Literature DB >> 11176762

Cost-effectiveness of endoscopy in irritable bowel syndrome.

S Suleiman1, A Sonnenberg.   

Abstract

BACKGROUND: It is unknown to what extent at what expense flexible sigmoidoscopy and colonoscopy add to the diagnosis of irritable bowel syndrome (IBS). The aim of the study was to assess the incremental cost-effectiveness of endoscopic procedures in the workup for IBS.
METHODS: Using the Bayes formula, we calculated the increase in diagnostic certainty for a consecutive number of tests. We also calculated the incremental cost-effectiveness ratio, which corresponds to the test costs divided by the increment in diagnostic certainty.
RESULTS: The diagnosis of IBS can be established with a relatively high probability of more than 80% relying on relatively inexpensive and noninvasive tests only. Flexible sigmoidoscopy or colonoscopy constitute the most costly portion of any workup for IBS, which amounts to 50% to 75% of the overall costs. Because of their high incremental cost-effectiveness ratio, endoscopic procedures should not be used at the beginning of the diagnostic workup. This outcome of the analysis remains largely unaffected within reasonable ranges of the sensitivity and specificity of various tests.
CONCLUSIONS: In the diagnosis of IBS, inexpensive, noninvasive tests should be used first to rule out other diagnoses. Despite their high incremental cost-effectiveness ratio, flexible sigmoidoscopy and colonoscopy are indicated when a serious organic disease is reasonably likely and needs to be ruled out.

Entities:  

Mesh:

Year:  2001        PMID: 11176762     DOI: 10.1001/archinte.161.3.369

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.

Authors:  Peipei Zhang; Xiaojing Liu; Aili Guo; Jing Xiong; Yu Fu; Kaifang Zou
Journal:  Dig Dis Sci       Date:  2016-04-07       Impact factor: 3.199

2.  Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case--control study.

Authors:  Hong-Xiang Gu; Ya-Li Zhang; Fa-Chao Zhi; Bo Jiang; Ying Huang
Journal:  Int J Colorectal Dis       Date:  2011-03-04       Impact factor: 2.571

Review 3.  Costs of irritable bowel syndrome in the UK and US.

Authors:  Stefanie Maxion-Bergemann; Frank Thielecke; Florian Abel; Rito Bergemann
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Do Socio-Demographics Play a Role in the Prevalence of Red Flags and Pursuant Colonoscopies in Patients With Irritable Bowel Syndrome?

Authors:  Anmol Mittal; Shivani Gupta; Faiz Afridi; Anthony Dimitrey; Sushil Ahlawat
Journal:  Cureus       Date:  2022-05-19

Review 5.  New developments in the diagnosis and treatment of irritable bowel syndrome.

Authors:  George F Longstreth; Douglas A Drossman
Journal:  Curr Gastroenterol Rep       Date:  2002-10

6.  Estimating the burden of irritable bowel syndrome: analysis of a nationwide korean database.

Authors:  Hye-Kyung Jung; Youn Hee Kim; Joo Yeon Park; Bo Hyoung Jang; Sun-Young Park; Mi-Hee Nam; Myung-Gyu Choi
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

7.  What calprotectin cut-offs should apply for IBD in general practice?

Authors:  Darryl Landis; Pali Hungin; Daniel Hommes
Journal:  Frontline Gastroenterol       Date:  2015-05-18

8.  Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey.

Authors:  K-S Ng; N Nassar; K Hamd; A Nagarajah; M A Gladman
Journal:  Colorectal Dis       Date:  2015-02       Impact factor: 3.788

Review 9.  Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.

Authors:  Marko Kumric; Piero Marin Zivkovic; Tina Ticinovic Kurir; Josip Vrdoljak; Marino Vilovic; Dinko Martinovic; Andre Bratanic; Ivan Kresimir Lizatovic; Josko Bozic
Journal:  Diagnostics (Basel)       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.